Lyell Immunopharma Inc
LYEL - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$270.54M
Close$
$0.51
95.3% downside
Current Fair Value
95.3% downsideOvervalued by 95.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $270.54 Million |
|---|---|
| Enterprise Value | $234.49 Million |
| Earnings per Share | $-16.06 |
| Beta | -0.07 |
| Outstanding Shares | 23,364,000 |
Return
| Return on Equity | -106.27% |
|---|---|
| Return on Assets | -79.86% |
| Return on Invested Capital | 49.59% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | -14.21 |
| Price to Sales | - |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 8684.64 |
| Enterprise Value to EBIT | 1.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-2.02
Consensus analyst estimateRevenue Estimate
$4,600
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-2.06
Consensus analyst estimateRevenue Estimate
$4,600
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 74.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 51.72% |
|---|---|
| Total Invested | $68,099▼ 99.96% |
| Investors Holding | 7▼ 84.00% |
About Lyell Immunopharma Inc
189 employees
